Sensei Biotherapeutics, Inc. announced it has entered into a Sponsored Research Agreement with Washington University in St. Louis, MO, to support development of SNS-101, a conditionally active VISTA-blocking antibody. Research will be conducted in the laboratory of Robert Schreiber, Ph.D., Professor of Pathology & Immunology and Director of the Center for Human Immunology and Immunotherapy Programs, to evaluate the underlying molecular mechanisms that enable SNS-101 to overcome myeloid cell-driven immunosuppression within the tumor microenvironment.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.65 USD | +30.95% | +64.98% | +138.44% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+138.44% | 31.6M | |
-1.65% | 104B | |
+6.75% | 97.47B | |
+5.71% | 22.25B | |
-12.60% | 21.68B | |
-9.70% | 18.2B | |
-39.98% | 17.02B | |
-10.17% | 16.36B | |
+6.12% | 14.39B | |
+35.47% | 12.37B |
- Stock Market
- Equities
- SNSE Stock
- News Sensei Biotherapeutics, Inc.
- Sensei Biotherapeutics Inc. Announces Collaboration with Washington University, St. Louis to Support Development of SNS-101, A Conditionally Active VISTA-Blocking Antibody